Endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) is currently the
standard first-line treatment for most patients with hormone receptor (HR) positive, human …

Simple Summary Abemaciclib, dalpiciclib, palbociclib and ribociclib have all demonstrated
significant improvements in progression-free survival in advanced disease. However, to …

The combination of an endocrine agent with a CDK4/6 inhibitor is the standard of care in the
first-line setting for patients with hormone receptor-positive, HER2-negative metastatic …

CDK4/6 inhibitors are remarkable anti-cancer drugs that can arrest tumor cells in G1 and
induce their senescence while causing only relatively mild toxicities in healthy tissues. How …

Simple Summary Breast cancers (BCs) with a HER2 immunohistochemical score of 1+ or 2+
with negative in situ hybridization are referred as HER2-low BCs. The knowledge about the …

Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer
therapy. However,< 50% of patients have an objective response, and nearly all patients …

Endocrine therapy (ET) in combination with CDK4/6 inhibition is routinely used as first-line
treatment for HR+/HER2− metastatic breast cancer (MBC) patients. However, 30–40% of …

Cyclin-dependent kinase (CDK) 4/6 inhibitors have significantly improved progression-free
survival in hormone-receptor-positive (HR+), human-epidermal-growth-factor-receptor-type …

CDK4/6 plays a crucial role in various cancers and is an effective anticancer drug target.
However, the gap between clinical requirements and approved CDK4/6 drugs is unresolved …

Background Breast cancer is the global leading cancer burden in women and the hormone
receptor-positive (HR+) subtype is a major part of breast cancer. Though cyclin-dependent …